Elevated Lp-PLA2 activity (per 1 SD) and greater stroke risk were observed consistently in subgroups, except for the subgroups defined as with a prospective cohort study design (RR 1.08; 95% CI 0.99–1.17), mean age ≥ 65 years, follow-up period ≥ 10 years, history of CVD (including coronary heart disease (CHD), stroke and TIA), NOS quality scores < 8 stars, or when men and women were analyzed separately (Supplement 6,7), which may be caused by inadequate numbers and low statistical power. Here, PLA2G7 is linked to stroke disorder.